Title Page
Zoltán Endre(Prince of Wales Hospital), R. Azoury, Jonathan L. Allis(John Radcliffe Hospital), Michael E. Stromski, S. Abrashkin, Terry L. Dowd(Albert Einstein College of Medicine), Adrian Iaina(Tel Aviv Sourasky Medical Center), Adrian laina, Renu Gupta(Guru Jambheshwar University of Science and Technology), Raj K. Gupta(Birla Institute of Technology and Science, Pilani), Joseph I. Shapiro, Charles W. Heilig, George K. Radda(Agency for Science, Technology and Research), Steven R. Gullans(Brigham and Women's Hospital), Adrian Spitzer(Albert Einstein College of Medicine), Laurence Chan(University of Oxford), Jon D. Blumenfeld(NewYork–Presbyterian Hospital), J. Weininger, M. Barac‐Nieto(Kuwait University)
Cited by 0
Related Papers
Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup
|Nature Reviews Nephrology|2017|1.5k
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
|The Lancet|2000|1k
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
|Journal of the American College of Cardiology|2000|731
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
|Journal of the American College of Cardiology|2001|646